NCT05887882 2026-03-16
PNOC028
University of California, San Francisco
Phase 1 Recruiting
Clinical Trials
14 trialsNCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT07330050 2026-01-09
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07144735 2025-08-27
ABOUT
Peking University Third Hospital
Phase NA Recruiting
NCT06926894 2025-07-31
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
Phase 1 Recruiting
NCT05617755 2025-07-30
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
Phase 1 Active not recruiting
NCT05183490 2024-12-30
R-MVST Cells for Treatment of Viral Infections
Columbia University
Phase 1 Recruiting
NCT05213195 2024-02-12
NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
Zhejiang University
Phase 1 Unknown
NCT02890758 2023-02-21
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Case Comprehensive Cancer Center
Phase 1 Completed
NCT05248048 2022-02-21
NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer
The Third Affiliated Hospital of Guangzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT03648697 2020-08-11
EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC
Fujian Cancer Hospital
Phase 2 Unknown
NCT03003728 2020-07-10
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
University of Arkansas
Phase 2 Withdrawn
NCT01186809 2019-01-23
CIK2
A.O. Ospedale Papa Giovanni XXIII
Phase 2 Completed
NCT01478074 2014-01-03
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Altor BioScience
Phase 1 Withdrawn